One of these very attractive targets for cancer therapy is the sodium-dependent phosphate transporter 2B (SLC34A2, NaPi2b, NaPi-IIb, and NPT2) which is overexpressed in several malignancies, including ovarian carcinomas (Rangel et al., 2003; Gryshkova et al., 2009), lung (Zhang et al., 2017), thyroid (Kim et al., 2010), and colorectal cancers (Liu et al., 2018). This evidence concerns the gene SLC34A2 and ovarian carcinoma.